Comments on:

FDA panel backs Gilead Sciences' hepatitis C drug

Back to the article » |
WASHINGTON (AP) — Food and Drug Administration advisers on Friday unanimously voted in favor of a highly anticipated hepatitis C drug from Gilead Sciences that holds promise for millions of Americans infected with the liver-destroying virus. All 15 members of the FDA's panel of virus experts voted to recommend approval of Gilead's pill, sofosbuvir, to treat several forms of hepatitis C....